Switching to tenofovir alafenamide in patients with virologically suppressed chronic hepatitis B and renal or hepatic impairment: final week 96 results from an open-label, multicentre, phase 2 study.
Janssen HLA, Lim YS, Lampertico P, Heo J, Chen CY, Fournier C, Tsang TYO, Bae H, Chen CH, Coffin CS, Ahn SH, Trinh H, Flaherty JF, Abramov F, Zhao Y, Liu Y, Lau A, German P, Chuang WL, Agarwal K, Gane E.
Janssen HLA, et al. Among authors: lim ys.
Lancet Gastroenterol Hepatol. 2024 Jun 17:S2468-1253(24)00096-7. doi: 10.1016/S2468-1253(24)00096-7. Online ahead of print.
Lancet Gastroenterol Hepatol. 2024.
PMID: 38901444